FDA's interim peptide policy is still under White House review, and its text isn't public. A physician group's statement names six peptides as being at issue. Peptide-medicine physicians and pharmacists want access through licensed pharmacies with safeguards. Critics question the evidence and the process. Review meetings are set for Wednesday and Friday.
